| abstract |
The present refers, in general, to antiviral agents. Specifically, the present refers to compounds that can inhibit the protein (s) encoded by the hepatitis B virus (HBV) or interfere with the function of the replication cycle of HBV, to compositions comprising these compounds, to methods to inhibit the replication of the HBV virus, to methods for treating or preventing HBV infection and to processes or intermediates for making the compounds. Claim 1: Compound of formula (1) in which Z is H, D, C (= O) N (R⁵) (R⁶), C (= O) N (R⁵) O (R⁶), C (= O) N (R⁵) N (R⁶) (R⁷), N (R⁵) (R⁶), N (R⁵) SO₂ (R⁶), C (= O) O (R⁵), CH₂-N (R⁵) (R⁶), C (R⁵) = NO (R⁶), O-R⁵, SO₂N (R⁵) (R⁶), SO₂-R⁵, alkyl, cycloalkyl, heterocycloalkyl, heteroaryl or heteroaryl substituted with C₂₋₆ alkenyl, wherein the cycloalkyl is optionally substituted with carboxy , carboxyl, halo, C₁₋₆ alkyl, C₁₋₆ haloalkyl or NH₂ ester; R¹ is H, D, F, Cl, Br, or NH₂; R²ᵃ, R²ᵇ, R²ᶜ and R²ᵈ are selected, for each position, independently from the group comprising H, CF₂H, CF₃, CF₂CH₃, F, Cl, Br, CH₃, Et, i-Pr, c-Pr, D, CH₂OH, CH (CH₃) OH, CH₂F, C (F) CH₃, I, C = C, C & |